September 21, 2012 (Investorideas.com newswire) GreeneStone Healthcare
Corporation (
OTCBB:GRST), provider of Mental Healthcare and
Corporate
Healthcare Services, today announced the hiring of Ann Kerr as Clinical
Director at its new Eating Disorder clinic. In addition to Ms. Kerr,
the
Company
has chosen a psychiatrist medical director, head psychologist, and
Chief Clinical Advisor, all of whom will formally be announced once they
are under contract. In addition the recently announced new hire, Dr.
Mohsina Chaklader, at the company’s ‘ Center of Excellence for
Gastroenterology’ will be a valuable resource for the Eating Disorder
clinic.
In the United States, as many as 10 million females and 1 million
males are suffering from an eating disorder such as anorexia and bulimia
and millions more are struggling with binge eating disorders. While
awareness of eating disorders is improving, the public, health care
providers and educators frequently have little understanding of eating
disorders, how to recognize symptoms and how to communicate with people
dealing with eating disorders. Eating disorders are very difficult to
treat and can require lifelong treatment. The goal of the Company will
be to stay with and support patients throughout their time of need,
while striving to achieve sufficient improvement so that in-patient care
is reduced and outpatient and ongoing care can begin.
Corporate Healthcare and disability costs are growing steadily
higher and effective treatment for those suffering from mental health
and mental health related issues will be the solution to reducing those
costs. The Company has an increasing number of specialists in the
treatment of mental health related disorders. “These are by far the
largest component of corporate healthcare costs,” stated Mr. Shawn Leon,
CEO. He added, “We see this as the biggest area of growth for the
Company and we need to be national in scope.”
Ann Kerr is a Registered Occupational Therapist and holds academic
appointments as Assistant Professor in the Department of Psychiatry, and
Lecturer in the Department of Occupational Therapy in the Faculty of
Medicine at The University of Toronto. She has worked in the field of
mental health for over 30 years and specialized in the care for people
affected by eating disorders through work in Inpatient, Day Hospital,
community, and private practice settings. Ann was part of the team that
built the Inpatient Eating Disorder Program at Toronto General Hospital
under Dr. Sid Kennedy, and then the first ever Eating Disorder Day
Hospital Program with Drs Allan Kaplan and Niva Piran. Ann accepted the
position of the first Program Director of Sheena’s Place, an innovative
model of support services for families and people with eating disorders.
Ann has been in private practice in Toronto for the past six years
honing her psychotherapy skills in the areas of CBT, DBT and Relational
Therapy.
Ann was trained at The University of Toronto and has ongoing
education through Harvard Medical School of Continuing Education and the
Jean Baker Miller Centre at Wellesley College. She has supervised
students in most health professions and been awarded the Northrop Frye
teaching award for medical student education. Ann was on the Board of
the Transitional College of Occupational Therapists and is a Member of
the College of Occupational Therapists of Ontario and the Ontario
Association of Occupational Therapists. She is a member of the Academy
of Eating Disorders, an international body of eating disorder clinicians
and researchers. Ann has written research articles and chapters in
books on the treatment of people with eating disorders as well as having
spoken at numerous conferences in Canada and the USA. She has appeared
frequently on television, radio and in newspapers and magazines
commenting on current issues in the culture that relate to this issue.
Limited operations at the Eating Disorder clinic are set to begin
in late October, with full service operations intended to commence in
early 2013. The primary mission of the clinic will be to treat anorexia
and bulimia through a combination of services, including in-patient
care, intensive outpatient care, ongoing support, after-care and
counseling. The company plans to offer the very best in care and hopes
to earn a reputation for the best care available in the country.
About GreeneStone Healthcare Corporation
GreeneStone Healthcare Corp. (GRST) is a provider of mental health
services, specializing in the areas of addiction treatment, eating
disorders, nutrition and weight loss, and executive healthcare.
GreeneStone is among the many nascent healthcare
companies
re-defining the healthcare space for the modern economy, which include
Roche Holding Ltd. (RHHBY), Sarepta Therapeutics Inc. (SRPT), Nektar
Therapeutics (NKTR), Celldex Therapeutics, Inc. (CLDX), Achillion
Pharmaceuticals, Inc. (ACHN), Zogenix, Inc. (ZGNX). The company operates
medical and healthcare clinics in Ontario, Canada, serving a North
American and international clientele. GreeneStone’s clinics meet several
ends: (1) GreeneStone adds overflow capacity to an increasingly
stretched public healthcare system in Canada, (2) GreeneStone mental
health clinics provide private alternatives to publicly available but
highly underserviced healthcare subsectors, and (3) GreeneStone meets
newly developing healthcare needs undisturbed by the public/private
market, such as eating disorders. The company is headquartered in
Toronto, Canada.
Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 (the “Securities
Act”) and Section 21E of the Securities Exchange Act of 1934 (the
“Exchange Act”). To the extent that any statements made in this press
release contain information that is not historical, these statements are
essentially forward-looking. Forward-looking statements can be
identified by the use of words such as “expect,” “plan,” “will,” “may,”
“anticipate,” “believe,” “should,” “intend,” “estimate,” and variations
of such words. Forward-looking statements are subject to risks and
uncertainties that cannot be predicted or quantified and, consequently,
actual results may differ materially from those expressed or implied by
such forward-looking statements. Such risks and uncertainties include,
without limitation, those risks and uncertainties contained in this
press release and those identified in the periodic reports that the
company files with the Securities and Exchange Commission (the “SEC”)
pursuant to the Exchange Act.
Investor information and email sign-up:
http://www.greenestoneinvestor.com
Contact:.
GreeneStone Healthcare Corporation
Shawn Leon, 416-222-5501
investor@greenestoneinvestor.com
www.greenestoneinvestor.com
Published at the Investorideas.com Newswire
Disclaimer/ Disclosure :
The Investorideas.com is a third party publisher of news and research
Our sites do not make recommendations, but offer information portals to
research news, articles, stock lists and recent research. Nothing on our
sites should be construed as an offer or solicitation to buy or sell
products or securities. This site is currently compensated by featured
companies, news submissions and online advertising. Disclosure:
Investorideas.com was compensated five hundred for the publication and
distribution of this news release .
BC Residents and Investor Disclaimer: Effective September 15 2008 -
all BC investors should review all OTC and Pink sheet listed companies
for adherence in new disclosure filings and filing appropriate documents
with Sedar. Read for more info:
http://www.bcsc.bc.ca/release.aspx?id=6894
About PositiveID Corporation 
About Sunshine Biopharma Inc. (OTCBB: SBFM): 
Neuralstem's patented technology enables the ability to produce
neural stem cells of the human brain and spinal cord in commercial
quantities, and the ability to control the differentiation of these
cells constitutively into mature, physiologically relevant human neurons
and glia. Neuralstem is in an FDA-approved Phase I safety clinical
trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou
Gehrig's disease, and has been awarded orphan status designation by the
FDA.